Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum bilirubin concentrations and their association with clinical and radiological outcomes in multiple sclerosis: A large cohort study.

Annals of hepatology·2025

Same author

Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024

Same author

Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024

Same author

A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.

Neurodegenerative disease management·2023

Same author

Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.

Journal of the neurological sciences·2023

Same author

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2023

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Freedom from disease activity in multiple sclerosis.

Eva Havrdova¹, Steven Galetta, Dusan Stefoski

¹Department of Neurology, First Faculty of Medicine, Charles University in Prague, Katerinska 30, 12808 Praha 2, Czech Republic. eva.havrdova@gmail.com

|April 28, 2010

Summary

Multiple sclerosis (MS) treatments can delay progression but not induce remission. Exploring definitions of remission and freedom from disease activity is crucial for assessing therapeutic response in MS.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jun 13, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

Neurology
Immunology
Clinical Therapeutics

Background:

Multiple sclerosis (MS) shares inflammatory pathways with other immune-mediated diseases like rheumatoid arthritis.
Biologics in rheumatoid arthritis shifted treatment goals towards disease remission.

Purpose of the Study:

To explore the concept of disease remission in MS.
To evaluate 'freedom from disease activity' as a measure of therapeutic response.

Main Methods:

Literature review and expert clinical opinion.
Discussion of potential definitions for MS remission.

Main Results:

Current MS therapies (interferon beta, glatiramer acetate) delay progression but do not achieve remission.
The concept of remission in MS is underexplored.

Conclusions:

Freedom from disease activity warrants further investigation as a key therapeutic outcome in MS.
Future research should assess the long-term impact of freedom from disease activity in relapsing-remitting MS.